Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study

Non-alcoholic fatty liver disease (NAFLD) comprises a heterogeneous group of metabolic liver diseases and is characterized by the presence of steatosis in at least 5% of hepatocytes. The aim of our study was to assess the effect of the combination therapy of empagliflozin + metformin vs. metformin m...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Alfredo Caturano, Raffaele Galiero, Giuseppe Loffredo, Erica Vetrano, Giulia Medicamento, Carlo Acierno, Luca Rinaldi, Aldo Marrone, Teresa Salvatore, Marcellino Monda, Celestino Sardu, Raffaele Marfella, Ferdinando Carlo Sasso
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2023-01-01
Colecção:	Biomedicines
Assuntos:	type 2 diabetes non-alcoholic fatty liver disease sodium-glucose cotransporter inhibitors metformin FibroScan<sup>®</sup> controlled attenuation parameter
Acesso em linha:	https://www.mdpi.com/2227-9059/11/2/322
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!